Frontiers in Oncology,
Journal Year:
2024,
Volume and Issue:
14
Published: Dec. 5, 2024
Standard
first-line
therapy
for
patients
with
metastatic
non-small
cell
lung
cancer
(mNSCLC)
without
identified
actionable
mutations
consists
of
regimens
comprising
immune
checkpoint
inhibitors
(ICIs),
alone
or
in
combination
platinum-based
chemotherapy
(CTx).
However,
approximately
20-30%
mNSCLC
(including
some
high
tumor
programmed
death
ligand-1
expression)
display
primary
resistance
to
ICIs,
either
CTx.
Mutations
suppressor
genes
Therapeutic Advances in Musculoskeletal Disease,
Journal Year:
2025,
Volume and Issue:
17
Published: Jan. 1, 2025
Psoriatic
arthritis
(PsA)
presents
various
clinical
manifestations,
including
skin
lesions,
peripheral
arthritis,
axial
involvement,
enthesitis,
nail
dactylitis,
and
uveitis.
In
addition,
it
causes
a
high
incidence
of
lifestyle-related
diseases
an
increase
in
cerebrovascular
cardiovascular
events.
As
the
pathology
PsA
has
been
clarified,
molecular-targeted
drugs
targeting
tumor
necrosis
factor-α,
interleukin
(IL)-17A,
IL-17A/F,
IL-17
receptor,
IL-12/23(p40),
IL-23p19,
Cytotoxic
T-lymphocyte
Antigen-4
(CTLA-4),
Janus
kinase,
phosphodiesterase-4
have
developed
are
widely
used
practice.
is
clinically
molecularly
heterogeneous,
necessary
to
improve
symptoms
with
limited
treatment
options
simultaneously;
therefore,
rheumatologists
sometimes
encounter
difficult
situations
Hence,
development
precision
medicine
may
outcomes.
Recently,
strategic
use
based
on
stratification
patients
by
blood
lymphocyte
phenotyping
serum
cytokine
concentrations
reported
possibly
lead
higher
therapeutic
response.
A
randomized
controlled
trial
was
initiated
verify
efficacy
this
strategy.
However,
make
feasible,
shifting
from
conventional
trials
biomarker
profiles
accumulating
further
data
necessary.
Pathology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 1, 2025
Molecular
testing
plays
a
critical
role
in
guiding
optimal
treatment
decisions
for
lung
cancer
patients
across
variety
of
clinical
settings.
While
guidelines
biomarker
exist
other
jurisdictions,
to
date
no
best
practice
have
been
developed
the
Australian
setting.
To
address
this
need,
Royal
College
Pathologists
Australasia
collaborated
with
Thoracic
Oncology
Group
identify
state-based
pathologists,
oncologists
and
consumer
representatives
develop
consensus
recommendations.
Sixteen
recommendations
were
established
encompassing
appropriate
biomarkers,
subtype,
tumour
stage,
specimen
types,
assay
selection
quality
assurance
protocols
that
can
inform
standardise
molecular
cancer.
These
multidisciplinary
evidence-based
are
designed
enhance
practices
cancers
should
help
ensure
laboratories
provide
high-quality
all
Australians,
including
those
from
regional
or
remote
communities.
Thoracic Cancer,
Journal Year:
2025,
Volume and Issue:
16(7)
Published: April 1, 2025
ABSTRACT
Immunotherapy
has
revolutionized
the
diagnosis
and
treatment
model
for
patients
with
advanced
non‐small
cell
lung
cancer
(NSCLC).
Numerous
clinical
trials
real‐world
reports
have
confirmed
that
PD‐L1
status
is
a
key
factor
successful
use
of
immunotherapy
in
NSCLC,
by
predicting
outcomes
identifying
most
likely
to
benefit
from
this
treatment.
Therefore,
accurate
standardized
evaluation
expression
crucial.
Currently,
testing
China
faces
several
challenges,
including
heavy
pathologist
workload,
shortage
highly
trained
pathologists
plus
inadequate
capacity
diagnostic
laboratories,
confusion
around
different
scoring
methods,
cut‐off
values,
indications,
limited
concordance
between
assays.
In
review,
we
summarize
current
limitations
NSCLC
discuss
recent
progress
artificial
intelligence‐assisted
scoring.
Our
review
aims
support
improvements
practice
optimization
prognosis
patient
population.
Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie,
Journal Year:
2024,
Volume and Issue:
149(S 01), P. S13 - S25
Published: Aug. 1, 2024
Optimal
personalized
treatment
planning
for
resectable
lung
cancer
requires
quality-assured,
standardized
and
prompt
processing
of
tissue
samples
in
pathological
laboratories,
as
well
the
determination
relevant
predictive
prognostic
biomarkers.
Pathological
diagnostic
testing
includes
histological
tumor
typing,
staging
grading,
resection
status
and,
if
necessary,
regression
grading
after
neoadjuvant
systemic
therapy.
Histopathological
typing
is
performed
according
to
current
WHO
classification
adenocarcinomas,
squamous
cell
carcinomas,
other
non-small
carcinomas
(NSCLCs),
carcinoids,
small
large
neuroendocrine
carcinomas.
Standardized
currently
plays
an
important
role
invasive
non-mucinous
adenocarcinoma
particular
enables
risk
assessment.
The
R
are
also
prognostically
relevant.
In
early
stages
NSCLC,
molecular
biomarkers
such
EGFR,
ALK
PD-L1,
decisions
on
individual
treatment.
Testing
FFPE
must
be
carried
out
a
quality-assured
manner
accordance
with
international
standards.
